Aberrant expression of CD56 on granulocytes and monocytes in myeloproliferative neoplasm
Tóm tắt
We reviewed CD56 expression on bone marrow (BM) granulocytes and monocytes by flow cytometry in 101 cases of myeloproliferative neoplasm (MPN) and compared them with those from 42 cases of myelodysplastic syndrome (MDS), 47 cases of negative BM after stem cell transplantation, and 24 cases of negative BM after chemotherapy. Forty cases of negative staging BM for lymphoma were used as negative controls. CD56 expression on granulocytes was also compared with corresponding morphologic and molecular genetic findings in five patients who underwent serial BM sampling. Using 10 % as positive threshold, aberrant CD56 expression was detected on granulocytes and monocytes in 20 and 34 % cases, respectively, in MPN, and in 18 and 36 % cases, respectively, in high-grade MDS. Aberrant CD56 expression was present in all subtypes of MPN with the highest frequency seen in primary myelofibrosis (37 % on granulocytes, 40 % on monocytes). Compared to monocytes, granulocytes had lower frequencies of CD56 expression but higher specificity for abnormal cells. Low levels of CD56 expression were detected on the granulocytes in normal BM after chemotherapy and stem cell transplantation, but the expression levels were generally below 10 %. In the patients with serial samples, CD56 expression paralleled with disease status by BM morphology, BCR/ABL1 transcripts, or percentage of BM recipient cells. We conclude that aberrant CD56 expression on granulocytes is present in a subset of patients in all subtypes of MPN. Identification of abnormal CD56-positive granulocytes is helpful in both initial diagnosis and follow-up of patients in MPN.
Tài liệu tham khảo
Swerdlow SH, Campo E, Harris NL, Jaffe ES, PIleri SA, Stein H, Thiele J, Vardman JW (2008) World Health Organization of classification of haematolymphoid malignancies, 4th edn. International Agency for Research in Cancer, Lyon
Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME (2001) Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98(4):979–987
Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Drager AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subira D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Bene MC, van de Loosdrecht AA (2012) Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 26(7):1730–1741
Lanza F, Bi S, Castoldi G, Goldman JM (1993) Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. Leukemia 7(10):1570–1575
Feng B, Verstovsek S, Jorgensen JL, Lin P (2010) Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis. Am J Clin Pathol 133(2):314–320
Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, Sestigiani C, Mariotti C, Birtolo S, Tozzi M, Lauria F (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 15(8):1161–1164
Ely SA, Knowles DM (2002) Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 160(4):1293–1299
Mann KP, DeCastro CM, Liu J, Moore JO, Bigner SH, Traweek ST (1997) Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol 107(6):653–660
Harrington A, Olteanu H, Kroft S (2010) The specificity of immunophenotypic alterations in blasts in nonacute myeloid disorders. Am J Clin Pathol 134(5):749–761
Dunphy CH (2011) Comparative analysis of detecting monocytic cells and their aberrancy. Appl Immunohistochem Mol Morphol 19(4):336–340
Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T (2011) Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. Leuk Lymphoma 52(1):92–100
Lacronique-Gazaille C, Chaury MP, Le Guyader A, Faucher JL, Bordessoule D, Feuillard J (2007) A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML. Haematologica 92(6):859–860
Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA (2008) Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 32(1):5–17
van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VH, Ossenkoppele GJ (2008) Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 111(3):1067–1077
Finnin M, Hamilton JA, Moss ST (1999) Characterization of a CSF-induced proliferating subpopulation of human peripheral blood monocytes by surface marker expression and cytokine production. J Leukoc Biol 66(6):953–960
Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH (2005) Flow cytometry analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol 124:799–806